EURECA Study: 2000 Patients and Counting

Facing the last months of the study, COMBACTE-CARE‘s EURECA has enrolled 2050 patients, achieving the sample of 2000 inclusions.

100% of the “matched packs” of the case/controls studies are now matched. With only the pneumonia subgroup pending to be completed, the team is currently overenrolling patients for some subgroups, avoiding final missings. The shipment of strains of included patients at Lab Central has been already started and final monitoring of information is being done.

The main goal in the coming months is to improve the inclusion rate of CRE episodes. Over 90% of estimated inclusions are already achieved; so we are in a good position even to include more cases than initially estimated.

Due to the delay in the activation of some sites included in the study and trying to ensure the achievement all the objectives, the period of recruitment has been officially extended until October 2018. The efforts and commitment of all active sites (currently 100% of selected sites are activated) ensures a constant inclusion rate that will enable the completion of study objectives on time.

Top enrolling sites in EURECA:

1. Hospital Universitario Carlos Haya (Dr. Jose Mª Reguera), Spain: 236 patients.
2. Hippokration Hospital of Thessaloniki (Dr. Emmanuel Roilides), Greece: 235 patients.
3. Hospital Universitario Reina Sofia (Dr. Julian De la Torre Cisneros), Spain: 196 patients.

The fruitful communication and collaboration between all COMBACTE collaborators, partners, national coordinators, and research teams proves the enormous value of the COMBACTE network, and that through it any objectives set forth can be achieved. The information provided by the study is interesting to both the scientific and global communities.

EURECA is a prospective observational study on cohorts of patients with serious carbapenem-resistant Gram-negative bacterial infections. It aims to study how patients across Europe are infected and currently treated, and which subgroups of patients respond well to which treatments.